Navigation Links
Certain new therapies for age-related eye disease do not appear to increase heart risks
Date:10/11/2010

Newer treatments for age-related macular degeneration (AMD)including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye diseasedo not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"More than 1.5 million older Americans have age-related macular degeneration, the most common cause of irreversible vision loss among older patients," the authors write as background information in the article. Of these, 12 percent have neovascular disease, which occurs when new blood vessels form in the eye and accounts for more than 80 percent of cases of severe vision loss. Before June 2006, there were two approved therapies for this condition, both of which slow vision loss but usually do not improve visual acuity: photodynamic (laser) therapy in combination with the photosensitizing medication verteporfin, and eye injections with pegaptanib octasodium, a nucleic blocking abnormal blood vessel growth.

By the fall of 2005, ophthalmologists began treating AMD with the cancer drug bevacizumab, an antibody that also blocks blood vessel growth. In June 2006, ranibizumaban antibody fragment with a similar mechanismwas approved by the Food and Drug Administration for treatment of AMD. "In chemotherapy regimens, bevacizumab is associated with an increased risk of thromboembolic events," when a blood clot forms and travels through blood vessels, potentially causing a stroke or heart attack, the authors write. "However, intravitreous bevacizumab is administered at a dose of 1 to 2.5 milligrams, 150 times less than the systemic dose. Despite the regulatory approval of ranibizumab, off-label use of bevacizumab continues, likely because of the cost difference ($1,950 per dose of ranibizumab vs. $30 per dose of bevacizumab. The relatively safety of the therapies is unknown."

Lesley H. Curtis, Ph.D., and colleagues at Duke University School of Medicine, Durham, N.C., and colleagues analyzed records from 146,942 Medicare beneficiaries who received treatment for AMD in 2005 or 2006. Reports of deaths, heart attacks, bleeding and stroke were tracked through 2007.

There were no differences in the risk of death or heart attack between the bevacizumab group and any other therapy group, and bleeding events or stroke did not differ by treatment group. Patients who received ranibizumab therapy were less likely to die or have a heart attack than those who received photodynamic therapy and less likely to have a heart attack than those given pegaptanib. The authors note that there is no evidence that photodynamic therapy and pegaptanib use is associated with increased risks of adverse systemic effects, so the differences may suggest residual confounding.

"In conclusion, we found no evidence of increased risks of mortality, myocardial infarction, bleeding or stroke among Medicare beneficiaries who received intravitreous ranibizumab or bevacizumab for neovascular age-related macular degeneration," the authors write.


'/>"/>

Contact: Debbe Geiger
Debbe.Geiger@duke.edu
919-660-9461
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. AGA offers new recommendations for CRC surveillance for certain patients with IBD
4. Smoking significantly increases risk of aneurysm in people with certain genes
5. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
6. Certain Bone Drugs May Lower Breast Cancer Risk
7. Football Injuries More Likely on Certain Artificial Turf
8. Plavix Can Help Cut Death Risk in Certain Heart Patients
9. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
10. Perhaps a longer lifespan, certainly a longer health span
11. One in Five Parents Would Spank in Certain Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: